Health Care & Life Sciences » Biotechnology | Genocea Biosciences Inc.

Genocea Biosciences Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
12,365.00
47,079.00
94,328.00
63,362.00
12,273.00
26,361
Total Accounts Receivable
-
21.00
-
-
-
-
Other Current Assets
510.00
942.00
865.00
926.00
808.00
696
Total Current Assets
12,875.00
48,042.00
95,193.00
64,288.00
13,081.00
27,057
Net Property, Plant & Equipment
865.00
1,956.00
4,083.00
4,871.00
3,460.00
2,582
Total Investments and Advances
158.00
316.00
12,420.00
316.00
316.00
316
Other Assets
1,863.00
117.00
446.00
421.00
631.00
1,160
Total Assets
15,761.00
50,431.00
112,142.00
69,896.00
17,488.00
31,115
ST Debt & Current Portion LT Debt
861.00
-
-
3,149.00
6,659.00
Accounts Payable
2,176.00
-
1,757.00
3,043.00
-
Other Current Liabilities
1,456.00
5,840.00
4,210.00
4,178.00
9,120.00
Total Current Liabilities
4,493.00
5,840.00
5,967.00
10,370.00
15,779.00
Long-Term Debt
8,933.00
11,488.00
16,477.00
13,809.00
7,652.00
Other Liabilities
904.00
596.00
37.00
176.00
107.00
Total Liabilities
14,330.00
17,924.00
22,481.00
24,355.00
23,538.00
Common Equity (Total)
80,131.00
32,507.00
89,661.00
45,541.00
6,050.00
Total Shareholders' Equity
1,431.00
32,507.00
89,661.00
45,541.00
6,050.00
Total Equity
1,431.00
32,507.00
89,661.00
45,541.00
6,050.00
Liabilities & Shareholders' Equity
15,761.00
50,431.00
112,142.00
69,896.00
17,488.00
Preferred Stock (Carrying Value)
81,562.00
-
-
-
-

About Genocea Biosciences

View Profile
Address
Cambridge Discovery Park
Cambridge Massachusetts 02140
United States
Employees -
Website http://www.genocea.com
Updated 07/08/2019
Genocea Biosciences engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine.